Cytori Therapeutics Inc (CYTX) : Cambridge Associates Adv has sold out all of its stake in Cytori Therapeutics Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 267 shares of Cytori Therapeutics Inc which is valued at $547.
Other Hedge Funds, Including , Guggenheim Capital sold out all of its stake in CYTX during the most recent quarter. The investment firm sold 3,782 shares of CYTX which is valued $7,753. Argentus Capital Management sold out all of its stake in CYTX during the most recent quarter. The investment firm sold 752 shares of CYTX which is valued $1,542. Spark Investment Management added CYTX to its portfolio by purchasing 21,100 company shares during the most recent quarter which is valued at $43,255. Raymond James Financial Services Advisors sold out all of its stake in CYTX during the most recent quarter. The investment firm sold 1,333 shares of CYTX which is valued $2,733.Msi Financial Services Inc boosted its stake in CYTX in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 51 shares of Cytori Therapeutics Inc which is valued at $104.
Cytori Therapeutics Inc opened for trading at $2 and hit $2.0899 on the upside on Thursday, eventually ending the session at $2.05, with a gain of 0.99% or 0.02 points. The heightened volatility saw the trading volume jump to 43,908 shares. Company has a market cap of $42 M.
On the company’s financial health, Cytori Therapeutics Inc reported $-0.43 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.39. The company had revenue of $1.10 million for the quarter, compared to analysts expectations of $3.00 million. The company’s revenue was down -31.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.06 EPS.
Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.